Perry Tal
Overview
Explore the profile of Perry Tal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
87
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Agarwal H, Tal P, Goldfinger N, Chattopadhyay E, Malkin D, Rotter V, et al.
Cell Death Differ
. 2024 May;
31(7):855-867.
PMID: 38745079
The p53 tumor suppressor, encoded by the TP53 gene, serves as a major barrier against malignant transformation. Patients with Li-Fraumeni syndrome (LFS) inherit a mutated TP53 allele from one parent...
2.
Tuval A, Brilon Y, Azogy H, Moskovitz Y, Leshkowitz D, Salame T, et al.
Haematologica
. 2022 Feb;
107(11):2548-2561.
PMID: 35199506
Pre-leukemic clones carrying DNMT3A mutations have a selective advantage and an inherent chemoresistance, however the basis for this phenotype has not been fully elucidated. Mutations affecting the gene TP53 occur...
3.
Tal P, Eizenberger S, Cohen E, Goldfinger N, Pietrokovski S, Oren M, et al.
Oncotarget
. 2019 Jun;
10(34):3203-3206.
PMID: 31191814
[This corrects the article DOI: 10.18632/oncotarget.10516.].
4.
Shetzer Y, Napchan Y, Kaufman T, Molchadsky A, Tal P, Goldfinger N, et al.
Int J Cancer
. 2016 Dec;
140(6):1364-1369.
PMID: 28008605
p53 loss of heterozygosity (LOH) is a frequent event in tumors of somatic and Li-Fraumeni syndrome patients harboring p53 mutation. Here, we focused on resolving a possible crosstalk between the...
5.
Oren M, Tal P, Rotter V
Aging (Albany NY)
. 2016 Jun;
8(6):1159-60.
PMID: 27347904
No abstract available.
6.
Tal P, Eizenberger S, Cohen E, Goldfinger N, Pietrokovski S, Oren M, et al.
Oncotarget
. 2016 Mar;
7(11):11817-37.
PMID: 26943582
The p53 tumor suppressor serves as a major barrier against malignant transformation. Over 50% of tumors inactivate p53 by point mutations in its DNA binding domain. Most mutations destabilize p53...
7.
Madar S, Harel E, Goldstein I, Stein Y, Kogan-Sakin I, Kamer I, et al.
PLoS One
. 2013 May;
8(4):e61353.
PMID: 23630584
Mutations in the p53 tumor suppressor protein are highly frequent in tumors and often endow cells with tumorigenic capacities. We sought to examine a possible role for mutant p53 in...